Beata Dobracka
Overview
Explore the profile of Beata Dobracka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Flisiak R, Zarebska-Michaluk D, Jaroszewicz J, Lorenc B, Klapaczynski J, Tudrujek-Zdunek M, et al.
Pol Arch Intern Med
. 2020 Feb;
130(2):163-172.
PMID: 32031541
No abstract available.
12.
Zarebska-Michaluk D, Piekarska A, Jaroszewicz J, Klapaczynski J, Mazur W, Krygier R, et al.
Adv Med Sci
. 2019 Dec;
65(1):12-17.
PMID: 31841821
Purpose: Since 2017 treatment-naïve patients infected with genotype 1b of hepatitis C virus and minimal or moderate fibrosis can be treated with Ombitasvir/Paritaprevir/ritonavir + Dasabuvir (OPrD) for 8 weeks according...
13.
Zarebska-Michaluk D, Jaroszewicz J, Buczynska I, Simon K, Lorenc B, Tudrujek-Zdunek M, et al.
J Gastroenterol Hepatol
. 2019 Nov;
35(7):1238-1246.
PMID: 31734959
Background And Aim: Grazoprevir/elbasvir (GZR/EBR) was approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infected patients with or without compensated liver cirrhosis. The aim...
14.
Zarebska-Michaluk D, Buczynska I, Simon K, Tudrujek-Zdunek M, Janczewska E, Dybowska D, et al.
Can J Gastroenterol Hepatol
. 2019 Apr;
2019:4029541.
PMID: 30941326
Background And Aim: The development of interferon- (IFN-) free regimens substantially improved efficacy of treatment for HCV, but despite excellent effectiveness the failures still occur. The aim of our study...
15.
Kiewra D, Szymanowski M, Zalewska G, Dobracka B, Dobracki W, Klakocar J, et al.
Int J Environ Health Res
. 2018 Jul;
28(5):502-510.
PMID: 29963907
To estimate the Lyme borreliosis (LB) risk for forest workers, totally 646 blood samples were tested for IgG and IgM anti-Borrelia burgdorferi s.l. (anti-B.b.) antibody occurrence using ELISA tests confirmed...
16.
Zarebska-Michaluk D, Flisiak R, Jaroszewicz J, Janczewska E, Czauz-Andrzejuk A, Berak H, et al.
J Interferon Cytokine Res
. 2018 Feb;
38(2):93-100.
PMID: 29443655
The aim of the study is to analyze treatments available for patients infected with genotype (G) 3 hepatitis C virus (HCV) in Poland at the beginning of the interferon (IFN)-free...
17.
Flisiak R, Pogorzelska J, Berak H, Horban A, Orlowska I, Simon K, et al.
Clin Exp Hepatol
. 2017 Sep;
2(4):144-148.
PMID: 28856279
The Aim Of The Study: Was to assess current prevalence of hepatitis C virus (HCV) genotypes in Poland, including their geographic distribution and changes in a given period of time....
18.
Flisiak R, Pogorzelska J, Berak H, Horban A, Orlowska I, Simon K, et al.
Clin Exp Hepatol
. 2017 Sep;
2(4):138-143.
PMID: 28856278
The Aim Of The Study: Was to analyze the efficacy achieved with regimens available for chronic hepatitis C (CHC) in Poland between 2013 and 2016. Material And Methods: Data were...
19.
Janczewska E, Flisiak R, Zarebska-Michaluk D, Kozielewicz D, Berak H, Dobracka B, et al.
Medicine (Baltimore)
. 2015 Sep;
94(38):e1411.
PMID: 26402801
We investigated the safety, efficacy, and impact of ribavirin and peginterferon dose reduction on complete early virologic response and sustained virologic response (SVR) to triple therapy with telaprevir in treatment-experienced...
20.
Dobracki W, Dobracka B, Paczosa W, Zieba J, Beres P
Przegl Epidemiol
. 2007 Oct;
61(2):385-91.
PMID: 17956058
The work presents epidemiological analysis of Borrelia burgdorferi (B.b.) infections and borreliosis cases in workers of the District Forestry Offices in Lower Silesia in 2003-2005. The infections rate was proved...